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DESCRIPTION of CASE
A 
31-year-old white male with no signiﬁ  cant past medical 
history is referred by his workplace to a primary 
care physician for an elevated blood pressure (BP). 
He presents to the clinic with no complaints. His mother 
and grandmother both have diabetes, and his father has 
hypertension. He has had a 15-pound (lb) weight gain over 
the last year and has become more sedentary.
His BP is 142/90 mm Hg, pulse is 88 beats per minute 
(bpm), weight is 209 lb, and height is 5' 11". On examination 
he displays moderate central obesity, but otherwise the 
examination is normal. His fasting cholesterol is 228 mg/dl 
(to convert milligrams per deciliter of cholesterol [total, HDL 
or LDL] to micromoles per liter, divide by 39), low-density 
lipoprotein (LDL) is 166 mg/dl, high-density lipoprotein 
(HDL) is 32 mg/dl, triglycerides (TG) are 223 mg/dl (to 
convert mg/dl of triglycerides to mmol/l, divide by 89), and 
fasting glucose is 114 mg/dl (to convert mg/dl of glucose to 
mmol/l, divide by 18).
What Is the diagnosis?
This patient meets the diagnostic criteria for the metabolic 
syndrome as deﬁ  ned by the National Cholesterol Education 
Program Adult Treatment Panel III guidelines [1]. Any 
three or more of the criteria make this diagnosis (see Table 
1). Intensive lifestyle modiﬁ  cations such as exercise and 
weight loss should be made to improve cholesterol, blood 
pressure, and other cardiovascular disease (CVD) risk factors 
[2]. It may be timely to address the prevention of diabetes 
in patients with metabolic syndrome since these patients 
are at high risk for development of type 2 diabetes. Lifestyle 
changes delay the onset or prevent the incidence of type 2 
diabetes in patients with glucose intolerance, a key feature of 
metabolic syndrome [3]. The patient is started on an exercise 
and weight loss program, sent for nutritional counseling, and 
scheduled for a return clinic appointment for three months 
later.
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Table 1. National Cholesterol Education Program Clinical 
Identiﬁ  cation of the Metabolic Syndrome
Risk Factor Deﬁ  ning Level
Abdominal Obesity Waist Circumference
  Men >40 in. (>102 cm)
  Women >35 in. (>88 cm)
TG ≥150 mg/dl (1.70 mmol/l)
HDL cholesterol
  Men <40 mg/dl (1.04 mmol/l)
  Women <50 mg/dl (1.30 mmol/l)
Blood Pressure ≥130/85 mm Hg
Fasting Glucose ≥110 mg/dl (6.12 mmol/l)
Adapted from [1].
DOI: 10.1371/journal.pmed.0020040.t001
DOI: 10.1371/journal.pmed.0020040.g001
Figure 1. Very Mild Diabetic Retinopathy
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Two Years Later
The patient returns to the clinic two years later. He presents 
with complaints of increasing frequency of urination and 
episodes of blurry vision. He has nocturia and has lost 
5 lb in the last week. Otherwise, his review of systems is 
unremarkable. His blood pressure is 146/88 mm Hg, pulse 
80 bpm, and weight 216 lb. His fundoscopic examination 
is normal. He continues to have moderate central obesity. 
Current medications are a thiazide diuretic, 12.5 mg once 
daily (QD), started one year prior. A non-fasting blood sugar 
is 267 mg/dl.
Can a diagnosis be made? There are three criteria for 
the diagnosis of type 2 diabetes as deﬁ  ned by the American 
Diabetes Association (ADA), of which any one is sufﬁ  cient 
to make the diagnosis (see Box 1). This patient meets the 
criteria for type 2 diabetes. He does not need to have a 
fasting blood sugar done because a random glucose greater 
than 200 mg/dl with symptoms of diabetes meets the ﬁ  rst 
criterion. Failing to comply with lifestyle modiﬁ  cation, his 
weight has increased 7 lb in two years and likely contributes 
to his development of diabetes. Of note, his recent weight 
loss is presumably due to overt hyperglycemia and glycosuria, 
further underestimating his true weight increase.
His additional investigations are as follows: fasting 
glucose, 215 mg/dl; hemoglobin A1c (HbA1c), 8.6%; and 
urine albumin-to-creatinine ratio, 2.0 mg/mmol (normal 
is <2.5 mg/mmol in men and <3.5 mg/mmol in women). 
LDL is 176 mg/dl, HDL 32 mg/dl, and TG 292 mg/dl. His 
electrocardiogram is normal.
What are the next steps in management at this time? 
Diabetes management should involve a multifaceted, goal-
directed approach, which includes dietary modiﬁ  cations, 
diabetes education, assessment of blood sugar readings, and 
pharmacotherapy. The ADA recommends glycemic and 
other CVD risk factor goals (see Table 2), in addition to foot 
evaluation and screening for nephropathy and retinopathy, 
for all adults with diabetes [4]. The patient is started on 
metformin, 500 mg twice daily (BID) with meals. Therapy 
with metformin appears to decrease the risk of diabetes-
related endpoints, including a reduction in cardiovascular 
events independent of glycemic control. There is also less 
weight gain and fewer hypoglycemic attacks than with 
insulin and sulphonylureas. Therefore, metformin may be 
an effective ﬁ  rst-line pharmacotherapy of choice in these 
patients [5]. There are several oral hypoglycemic agents (i.e., 
sulfonylureas, metformin, acarbose, and thiazolidinediones) 
that are effective monotherapy for reducing hyperglycemia.
The patient is also started on low-dose aspirin, indicated 
for primary prevention of macrovascular disease in people 
with diabetes who have any risk factors for CVD [4], and a 
cholesterol-lowering agent, a statin, for his increased LDL 
cholesterol [6]. He is given a glucose meter, is scheduled 
to have diabetes education classes and diabetes nutritional 
counseling for a 1,800-calorie ADA diet, and is instructed 
to record his pre-meal blood sugars. Smoking cessation is 
another important aspect of diabetes management to address. 
He returns in three months for follow-up and has an HbA1c 
of 7.3%, at which time no additional therapy is started. 
Three Years Later
The patient is now 37 years old and returns for a follow-up 
appointment. He states that he has felt “pins and needles” in 
his feet and ﬁ  ngertips. He has had difﬁ  culty with maintaining 
erections but has a normal libido. Blood sugars are 160–190 
mg/dl in the mornings and 200–240 mg/dl in the evenings, 
and the patient reports no hypoglycemic events. He has 
diminished sensation to vibration over his right great toe and 
left toes and heel with intact monoﬁ  lament sensation. The 
remainder of his examination is unchanged. His medications 
are metformin at 1 g BID, a thiazide diuretic at 25 mg QD, a 
statin QD, and an aspirin QD. He is 215 lb, BP is 142/86 mm 
Hg, and pulse is 76 bpm. Recent laboratory tests produced 
the following results: a HbA1c of 8.1%, a fasting glucose of 
212 mg/dl, and normal electrolytes, creatinine, and liver 
enzymes. Fasting lipids are LDL 144 mg/dl, HDL 33 mg/dl, 
and TG 209 mg/dl.
What additional diagnostic tests would be helpful at this 
time, and why? A spot urine albumin-to-creatinine ratio is 7.6 
mg/mmol. This measurement technique is preferred because 
it has lower rates of false-positive and false-negative results 
than a spot urine microalbumin. Persistent microalbuminuria 
should be conﬁ  rmed on two or three subsequent readings 
within a six-month period to rule out false-positive results. 
The elevated ratio of microalbumin in the urine signiﬁ  es 
early nephropathy because microalbuminuria has been shown 
to progress to macroalbuminuria and eventual nephropathy 
in type 1 and type 2 diabetes. Any degree of albuminuria 
is a risk factor for cardiovascular events in individuals with 
or without diabetes; the risk increases with the level of 
absolute microalbuminuria [7]. Therefore, screening for 
microalbuminuria should be done annually in all people with 
type 1 and type 2 diabetes [8].
Annual screening for diabetic retinopathy should be 
performed in all people with diabetes after an initial 
evaluation and reassessed more frequently if retinopathy 
Box 1. ADA Diagnostic Criteria for Type 2 Diabetes
1. Random plasma glucose ≥200 mg/dl (11.1 mmol/l) and 
symptoms or
2. Fasting plasma glucose ≥126 mg/dla (6.99 mmol/l) or
3. Two-hour plasma glucose ≥200 mg/dla (11.1 mmol/l) in oral 
glucose tolerance test.
aIn the absence of symptoms, these criteria should be conﬁ  rmed 
by repeat testing on a different day.
Source: [28].
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Figure 2. Non-Proliferative Diabetic Retinopathy Showing Several 
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is diagnosed. This patient remains free of retinopathy, but 
a signiﬁ  cant number of patients with type 2 diabetes have 
retinopathy at the onset of diagnosis owing to the insidious 
nature of type 2 diabetes and the failure to diagnose type 2 
diabetes early. Tight glycemic control can slow the progression 
of diabetic retinopathy (Figures 1–3) [9] and help prevent 
development of proliferative diabetic retinopathy. 
What additional pharmacotherapy should be started 
at this time? The patient has developed neuropathy and 
erectile dysfunction, both of which are complications of 
diabetes. He continues to have suboptimal glycemic control; 
therefore, additional therapy in the form of combinations 
is appropriate. The patient is started on a thiazolidinedione 
(TZD) QD. With continued elevated systolic BP >130 mm 
Hg and diastolic BP >80 mm Hg, an angiotensin-converting 
enzyme inhibitor (ACE-I) is started. An ACE-I at this 
time is appropriate for BP control and has the additional 
preventative effects of reducing progression to nephropathy 
and CVD events [10,11]. In addition, continued strict BP 
control is as effective as tight glycemic control in preventing 
macrovasular disease in diabetic patients and slowing the 
progression of diabetic nephropathy and retinopathy [12]. 
Erectile dysfunction is a complication associated with diabetes 
and can be an early sign of neuropathy and vascular disease, 
therefore a phosphodiesterase-5 enzyme inhibitor is an 
appropriate choice for patients not on vasodilators or with 
a history of signiﬁ  cant CVD. The statin dose is increased to 
achieve a goal LDL of ≤100 mg/dl. Diabetic neuropathy is a 
signiﬁ  cant cause of morbidity in diabetes, and its progression 
correlates directly with glycemic control. Tighter glucose 
control and proper foot care are effective. It is important 
to continue emphasis on dietary, exercise, and lifestyle 
modiﬁ  cations in addition to pharmacotherapy. 
Five Years Later
The patient returns to clinic today after spending the last 
three years overseas and has not seen a physician in two years. 
He complains of fatigue, occasional blurry vision, awakening 
three to four times at night to urinate, and diarrhea at least 
once a week. He says that he has been compliant with his 
diabetes medications but has gained 15 lb in the last six 
months. His medications include metformin at 1 g BID, a 
TZD BID, and an ACE-I QD. His blood sugar is 289 mg/
dl (fasting), BP is 130/90 mm Hg, pulse is 88 bpm, and 
weight is 221 lb. There are no foot sores or ulcers, but he 
has diminished sensation to monoﬁ  lament on the plantar 
surfaces of both feet. The remainder of his examination 
is unchanged, including normal fundoscopy. His HbA1c 
is 9.6%, LDL is 143 mg/dl, and spot urine albumin-to-
creatinine ratio is 15 mg/mmol. His creatinine and liver 
enzymes are normal. His pre-meal blood sugars average 
210–250 mg/dl.
What is the next most appropriate step in his medical 
management? He continues to have an elevated HbA1c, 
worsening neuropathy, and weight gain, which prompt a 
more effective treatment strategy. There are several options 
for pharmacotherapy available to choose from at this point. 
The patient could begin a third oral agent after maximizing 
the doses of metformin and TZD, or he could begin insulin 
injections with or without additional oral agents. Because of 
the signiﬁ  cant cost associated with three oral medications 
and his need for further glycemic control, insulin would 
be an appropriate choice at this time. However, he should 
be advised of the side effect of additional weight gain when 
beginning insulin therapy.
DISCUSSION
This case presentation illustrates an otherwise healthy 
appearing patient who is found to have the metabolic 
syndrome and despite evidence-based management develops 
type 2 diabetes. This patient likely represents the natural 
history of type 2 diabetes in most patients. Mild hypertension 
is often the only presenting sign of metabolic syndrome and 
prediabetes, allowing an opportunity for prevention of type 2 
diabetes. 
There is an association between metabolic syndrome and 
the development of CVD and type 2 diabetes [13]. This 
syndrome is characterized not only by the criteria given in 
Table 1, but also by a state of compensatory hyperinsulinemia 
[14]. However, a diagnosis of metabolic syndrome alone 
does not imply diabetes, as patients with metabolic syndrome 
can have a fasting plasma glucose less than 110 mg/dl. 
It is the body’s ability to maintain glucose utilization and 
suppress endogenous glucose production in the setting of 
this compensatory hyperinsulinemia that separates metabolic 
syndrome from diabetes. The effect of this hyperinsulinemic 
state in metabolic syndrome is also believed to be involved 
in excess pro-inﬂ  ammatory and pro-thrombotic markers 
associated with the development of diabetes and CVD [15]. 
These patients develop diabetes when tissues of the body fail 
to utilize glucose appropriately owing to increased resistance 
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Figure 3. Non-Proliferative Diabetic Retinopathy Showing Macular 
Edema, a Cotton-Wool Spot below the Optic Disk, and a Few 
Hemorrhages and Exudates
Table 2. ADA Summary of Goals in Adult Patients with Diabetes
Factor Goal Level
Glycemic control  HbA1c < 7.0%
Preprandial plasma glucose  90–130 mg/dl (5.0–7.2 mmol/l)
Postprandial plasma glucose  <180 mg/dl (10 mmol/l)
Blood pressure  <130/80 mm Hg
Lipids
  LDL <100 mg/dl (2.6 mmol/l)
  TG <150 mg/dl (1.7 mmol/l)
  HDL >40 mg/dl (1.04 mmol/l)
Source: [4].
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to insulin and concomitant beta-cell dysfunction of the 
pancreas [16].
Metformin is in the class of biguanides and works by 
decreasing hepatic glucose output and increasing insulin 
action in tissues. Metformin has been suggested to help 
prevent the onset of diabetes but is less effective than diet and 
lifestyle changes [3]. Other medications shown to possibly 
delay or prevent the onset of type 2 diabetes are ACE-I and 
angiotensin II receptor blockers [17,18]. Patients treated with 
diuretics can progress to type 2 diabetes even though thiazide 
diuretics are proven effective in treating hypertension 
[19,20].
Intensive therapy in patients with type 2 diabetes results in 
a decreased risk of microvascular complications; therefore, it 
is appropriate to use combinations of medications in patients 
with suboptimal glycemia [21]. The class of TZDs works to 
lower plasma glucose levels by increasing insulin sensitivity 
in muscle and liver [22]. TZDs lower mean HbA1c modestly 
when added to metformin as compared to metformin alone 
[23]. Side effects include weight gain and water retention, 
and patients with a history of New York Heart Association 
class III or IV heart failure should not use TZDs [24,25].
The pathophysiology of type 2 diabetes involves, in 
part, a “relative” deﬁ  ciency of insulin. Although a state of 
endogenous hyperinsulinemia occurs, the degree of tissue 
resistance causes a total decrease in “effective” endogenous 
insulin. Progression of disease is also attributed to worsening 
beta-cell dysfunction and decreased release of insulin 
[26]. Insulin is used in a variety of combinations and is 
individualized to patient lifestyle. A frequent starting dose 
consists of a long- or intermediate-acting insulin, such as NPH 
insulin, divided into morning and evening doses, or insulin 
glargine given QD, usually at bedtime. The patient whose 
case is described here was started on NPH at bedtime, which 
decreases overnight hepatic glucose production such that the 
patient begins the morning with near-normal glycemia for 
daytime oral therapy. There may be times when a post-meal 
surge in glucose requires extra insulin in addition to the 
intermediate-acting NPH. In such a case, using a short-acting 
(regular) insulin before meals provides insulin action that 
closely approximates normal insulin secretion (Figure 4). The 
rapid-acting lispro and aspart insulins have an even shorter 
half-life and quicker onset of action than regular insulin. 
Common empirical initiation doses range from 0.4–1.2 
units of insulin per kilogram per 24 hours. Patients should 
be advised of hypoglycemia and weight gain as the main 
side effects of insulin therapy. Insulin and insulin-sensitizer 
combinations signiﬁ  cantly improve hyperglycemia; however, 
there is an increased incidence of heart failure reported with 
this combination, prompting close monitoring of patients for 
signs and symptoms of heart failure [27].
In summary, diabetes prevention and management is an 
important goal in practice. The morbidity and mortality from 
diabetes is a signiﬁ  cant burden to health care, emphasizing 
the need for effective prevention and control of diabetes in 
improving outcomes.  
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Key Learning Points
• The natural history of diabetes suggests that it is a progressive 
disease, and therapy may need to be frequently changed or 
augmented over time. 
• The diagnosis of the metabolic syndrome should alert primary 
care physicians to prescribe intensive lifestyle modiﬁ  cations for 
prevention of diabetes.
• Strict BP, lipid, and weight control is just as essential as strict 
glycemic control in preventing CVD in patients with diabetes.
• Metformin can reduce the risk of CVD in obese patients with 
diabetes independent of glycemic control.
• The decision of combination oral therapy with or without 
insulin should be individualized to optimize glycemic control 
and reduce micro- and macrovascular complications.